Sponsored Post Being diagnosed with a rare, chronic blood cancer like essential thrombocythemia, or ET, can feel overwhelming and isolating. In the United States, approximately 24 out of every 100,000 people are currently living with ET. Because ET is uncommon, it may be hard to know where to turn for clear, trustworthy information—especially early in […]
How I Achieved Complete Molecular Remission From Polycythemia Vera (PV)
by David Wallace, Founder, PV Reporter & MPN Cancer Connection When I was first diagnosed with polycythemia vera, nobody told me that PV remission was even possible. And the only treatment I was given, phlebotomy alone, guaranteed it wouldn’t be. Today, my blood counts are normal and the molecular markers driving my PV are undetectable. […]
One Pill, Once a Day: FDA Approves Jakafi XR
Summary Ruxolitinib, the cornerstone treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease, just got easier to take. On May 1, 2026, the FDA approved Jakafi XR™, a once-daily extended-release tablet formulation of the same proven drug. It will be available at pharmacies as early as May 8. Key Points Same medicine, simpler schedule: Jakafi XR […]
Remembering Dr. Richard T. Silver (1929–2026): MPN Pioneer
by David Wallace Dr. Richard T. Silver died on April 17, 2026, at the age of 97. He was born on January 18, 1929. In the 97 years between those two dates, he built a career that is difficult to summarize without sounding like a highlight reel, and yet every line of it is true. […]
Interferon for Myelofibrosis: 2025 Study Challenges “Watch and Wait”
by David Wallace For years, the medical community has told us the same thing when we’re diagnosed with early-stage myeloproliferative neoplasms: “Let’s watch and wait.” The thinking was straightforward: why expose someone to treatment side effects when they’re not yet symptomatic? But a study published this December in the journal Cancers is challenging that entire […]
- 1
- 2
- 3
- …
- 46
- Next Page »
